Bank of Nova Scotia
BMRN icon

Bank of Nova Scotia’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bank of Nova Scotia’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,533
Closed -$2.17M – 1096
2025
Q4 		$2.17M Buy
36,533
+25,725
+238% +$1.4M ﹤0.01% 775
2025
Q3 		$585K Buy
10,808
+1,427
+15% +$81.6K ﹤0.01% 865
2025
Q2 		$516K Sell
9,381
-3,652
-28% -$215K ﹤0.01% 851
2025
Q1 		$921K Sell
13,033
-2,474
-16% -$166K ﹤0.01% 751
2024
Q4 		$1.02M Buy
15,507
+2,083
+16% +$140K ﹤0.01% 780
2024
Q3 		$944K Sell
13,424
-580
-4% -$48.5K ﹤0.01% 770
2024
Q2 		$1.15M Sell
14,004
-139,978
-91% -$11.7M ﹤0.01% 751
2024
Q1 		$13.4M Sell
153,982
-123,486
-45% -$11.1M 0.03% 344
2023
Q4 		$26.8M Buy
277,468
+4,611
+2% +$408K 0.05% 256
2023
Q3 		$24.1M Buy
272,857
+145,685
+115% +$13M 0.06% 205
2023
Q2 		$11M Buy
127,172
+24
+0% +$2.26K 0.03% 272
2023
Q1 		$12.4M Sell
127,148
-88,901
-41% -$9.22M 0.04% 249
2022
Q4 		$22.4M Buy
216,049
+211,797
+4,981% +$19.9M 0.06% 222
2022
Q3 		$360K Sell
4,252
-416
-9% -$37K ﹤0.01% 1018
2022
Q2 		$399K Sell
4,668
-1,238
-21% -$98.6K ﹤0.01% 1041
2022
Q1 		$455K Buy
5,906
+2,311
+64% +$193K ﹤0.01% 1060
2021
Q4 		$320K Buy
+3,595
New +$297K ﹤0.01% 1147
2019
Q4 		– Sell
-83,902
Closed -$5.66M – 919
2019
Q3 		$5.66M Buy
+83,902
New +$6.46M 0.02% 475

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of Nova Scotia's BMRN Position: Q1 2026 in Review

Bank of Nova Scotia sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 36,533 shares — an estimated $2.17M sold.

Bank of Nova Scotia first reported a position in BMRN in Q3 2019 and held it in 18 quarters. The position peaked at $26.8M in Q4 2023. 557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Bank of Nova Scotia reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of Nova Scotia sold 36,533 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.17M.
  • Bank of Nova Scotia first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 18 quarters.
  • Bank of Nova Scotia's BioMarin Pharmaceuticals position peaked at $26.8M in Q4 2023.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.